The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in people with HIV is relatively common. Dr Richard Sterling (Virginia Commonwealth University, Richmond, VA, USA) joins touchINFECTIOUS DISEASES to discuss the pathogenesis and factors associated with the development of fatty liver in people with HIV, biomarkers proven effective for NAFLD in HIV, and the research priorities in HIV-associated NAFLD.
The presentation entitled: ‘Diagnosis and Epidemiology of NAFLD/NASH in HIV–Unique Opportunities and Challenges’ was presented at the American Conference for the Treatment of HIV (ACTHIV), May 5-7, 2022.
- Could you give us a brief overview of the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in people with HIV?
- What is known about the pathogenesis of NAFLD in HIV?
- What factors are associated with the development of fatty liver in people with HIV?
- What biomarkers have proven effective for NAFLD in HIV?
- What are the research priorities in HIV-associated NAFLD and what studies are ongoing?
Disclosures: Richard Sterling receives or has received grant/research Support from Abbie, Abbott, Gilead, and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In HIV
Moti Ramgopal, IDWeek 2022: Unmet needs and challenges around maintenance of HIV-1 virologic suppression
In this touchINFECTIOUS DISEASES interview, we met with Dr Moti Ramgopal (Midway Research Center, FL, USA) to discuss the unmet needs and challenges around maintenance of HIV-1 virologic suppression. Dr Ramgopal discusses challenges around stigma, social issues, tolerability, injection site reactions, and patient satisfaction with their current treatment regimen. Access an interview with Dr Moti […]
Moti Ramgopal, IDWeek 2022: Phase 3/3b FLAIR and ATLAS-2M pooled analysis – Efficacy and safety outcomes through week 96 by race
Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for […]
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!